IP Group CEO on £30m exits, targets £250m by 2027

IP Group PLC reported robust first-half cash realisations of £30.3 million, significantly exceeding the prior year and positioning the company to meet its £50 million FY25 target and over £250 million by 2027. CEO Greg Smith noted encouraging portfolio developments, including Hinge Health's successful NYSE IPO and Oxford Nanopore beating guidance, alongside a stabilized NAV per share and increased M&A interest. The firm maintains confidence in its exit strategy, balancing share buybacks with supporting its well-funded portfolio through upcoming milestones, benefiting from improved public market liquidity.

Analysis

IP Group PLC has demonstrated a significant acceleration in its value realisation strategy, generating £30.3 million in cash from exits in H1 2025, a nearly nine-fold increase compared to the £3.3 million in H1 2024. This performance places the company firmly on track to meet its £50 million target for FY25 and lends credibility to its longer-term goal of achieving over £250 million in cash realisations by 2027. The positive momentum is underpinned by specific portfolio successes, including the successful IPO of Hinge Health, whose shares have appreciated approximately 80% post-listing, and Oxford Nanopore's better-than-expected results. Concurrently, Net Asset Value (NAV) per share has stabilized and recovered to approximately £1 post-period, supported by a rebound in public holdings. Management is executing a disciplined capital allocation policy, prioritizing accretive share buybacks—having retired 14% of share capital to date—and supporting its existing portfolio, which is reportedly well-funded with nearly two-thirds of holdings financed through to 2026. The improving environment for IPOs and rising M&A interest provide a favorable backdrop for future exits, with a pipeline of milestones including trials for Istesso and commercial progress at Hysata expected to provide further catalysts.

Key Decisions for Investors

• Investors should note the significant acceleration in cash realisations and management's high confidence in meeting near and long-term exit targets, with the November expiry of the Hinge Health lock-up representing a key potential catalyst for further value crystallisation.
• The ongoing share buyback program, which has already retired 14% of share capital, signals management's belief that the stock is undervalued relative to its NAV of approximately £1 per share, offering a potentially accretive opportunity for long-term shareholders.
• Monitor the execution of key portfolio milestones, such as Istesso’s phase two trial and Hysata’s hydrogen rollout in Saudi Arabia, as these events are critical for validating the portfolio's long-term value and supporting the path to the £250 million exit target by 2027.
• Given that approximately two-thirds of the portfolio is funded through to 2026, near-term financing risk appears muted, allowing investors to focus on the company's ability to execute on its monetisation strategy in the improving market for IPOs and M&A.